Immune Tolerance Network (ITN)


At a Glance
  • Status: Active Consortium
  • Year Launched: 2010
  • Initiating Organization: National Institutes of Health
  • Initiator Type: Government
  • Disease focus:
    Allergy, Asthma, Autoimmune Diseases, Transplantations
  • Location: North America
ITN

Abstract

The Immune Tolerance Network (ITN) is a collaborative network for clinical research, funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The organization’s mission is to accelerate the clinical development of immune tolerance therapies.

Mission

ITN is an organization born from the collective vision of NIAID and the tolerance research community. As such, the vision and the principles upon which the organization was founded are a reflection of the community itself.

The Statement of Values and Commitments clearly defines these principles and provides a framework that guides ITN in its activities. This commitment ensures that it will continue as a strong advocate for the community in an open and accessible manner.

ITN’s mission is to advance the clinical application of immune tolerance by performing high-quality clinical trials of emerging therapeutics integrated with mechanism-based research.

In particular, ITN aims to:

Financing

ITN is sponsored by NIAID, with support from the Juvenile Diabetes Research Foundation. Additional funding has also been provided through the special Type 1 diabetes appropriation overseen by the National Institute of Diabetes, Digestive and Kidney Diseases.

Data Sharing

ITN’s data sharing policy is published on its website. The document includes ITN policies for when and how clinical, specimen, and mechanistic study data will be released to the public, including how such release will be limited to protect participant privacy. The ITN TrialShare web portal is the primary mechanism of data sharing and therefore the main focus of the policy.

ITN conducts research and clinical trials in the following areas: allergy and asthma, autoimmune disease, transplantation, and Type 1 diabetes. The research activities, including clinical trials that are looking for patients to enroll, for each disease are available on ITN’s website.

ITN’s accomplishments are as follows:

Homepage

http://www.immunetolerance.org/

Sponsors & Partners

Office of the Director

Benaroya Research Institute
1201 Ninth Avenue
Seattle, WA 98101-2795
phone: 206-342-6901
fax: 206.342.6588

Gerald Nepom, M.D., Ph.D.
Network Director
phone: 206-342-6515
email: director@immunetolerance.org

Mary Roy
Administrative Director
phone: 206-342-6512
email: mroy@immunetolerance.org

Research Funding, Application and Communication Inquiries

Philip Bernstein, Ph.D.
Executive Director, Strategic Review, Planning and Communications
phone: 240-235-6132
email: pbernstein@immunetolerance.org

Bioinformatics & TrialShare

Adam Asare, Ph.D.
Executive Director, Bioinformatics Group
phone: 240-235-6149
email: aasare@immunetolerance.org

Vince Carey, Ph.D.
Scientific Director, Bioinformatics Group
phone: 617-525-2265
email: stvjc@channing.harvard.edu


Last Updated: 04/22/2016

The Consortia-pedia Catalogue is a living resource, and we are always adding new consortia. Provide information here about your collaboration to apply to be included in the Catalogue.

All the information contained in the Consortia-pedia was collected from publically available sources. Decisions to include or exclude a particular listing from Consortia-pedia were also made on the basis of publically available information and the criteria outlined in the FAQs. This site is intended to be an objective resource for the community, and inclusion does not constitute or imply endorsement, recommendation, or approval by FasterCures or the Milken Institute.